<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01783301</url>
  </required_header>
  <id_info>
    <org_study_id>11/QD-CGRH-NCKH&amp;DT</org_study_id>
    <nct_id>NCT01783301</nct_id>
  </id_info>
  <brief_title>Anti-Mullerian Hormone (AMH) Versus Antral Follicle Count (AFC) Guided rFSH Dosing Study</brief_title>
  <official_title>A Phase IV, Open-label 2 Arm Trial to Compare the Efficacy and Safety of a Pre-defined Dose of GONAL-f® Based on Antral Follicle Count [Follicles ≥2mm - &lt;11mm]), or AMH for Ovarian Stimulation in Subjects Undergoing Assisted Reproductive Technology (ART) Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vietnam National University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono Vietnam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vietnam National University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objectives of this trial are to:&#xD;
&#xD;
        -  To explore the efficacy and safety of using either antral follicle count (AFC) or&#xD;
           anti-Mullerian hormone (AMH) to guide the starting dose of GONAL-f® in ovarian&#xD;
           stimulation for Assisted Reproductive Technology (ART).&#xD;
&#xD;
        -  To assess the differences in both ovarian response and clinical pregnancy rate between&#xD;
           subjects with different AFC and AMH levels undergoing ART.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial design&#xD;
&#xD;
      This trial is a prospective, Phase IV 2 arm trial exploring the efficacy and safety of using&#xD;
      either AFC or AMH to guide the starting GONAL-f® dose for the stimulation treatment of&#xD;
      subjects undergoing ART.&#xD;
&#xD;
      Throughout the trial period and before the start of a routine ART cycle, investigators will&#xD;
      propose the trial to their potential subjects. All subjects who agree to participate in the&#xD;
      trial must sign a consent form, irrespective of whether or not they ultimately agree to have&#xD;
      their dose determined by the study protocol. Eligible subjects will be randomised in blocks&#xD;
      of 4 at each site via a computer generated random number list to either the AFC guided arm&#xD;
      (control) or the AMH guided arm (treatment). The starting doses of GONAL-f® for each arm will&#xD;
      be based on the study algorithms, using AFC or AMH guidance.&#xD;
&#xD;
      The investigator will then enter initiate ovarian stimulation with an individualised GONAL-f®&#xD;
      dose for that specific subject. This will be maintained for the first 5 days of stimulation&#xD;
      after which the dose can be modified based on investigator decision and in accordance with&#xD;
      the site's routine clinical practice.&#xD;
&#xD;
      Trial Population&#xD;
&#xD;
      Female partners of infertile couples requiring Assisted Reproductive Technology (ART)&#xD;
      treatment.&#xD;
&#xD;
      Data Analysis and Statistics&#xD;
&#xD;
      The primary end-point proportion of patients with desired number of retrieved oocytes (8-12)&#xD;
      will be compared between the 2 arms using the chi -square test. The null hypothesis will be&#xD;
      that there is no difference between the 2 arms in primary end-point, with the p level set at&#xD;
      p=0.05. The secondary end-points will also be compared between the 2 arms using either the&#xD;
      Student's t test or anova test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>30 minutes after oocyte retrieval completed</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms of ovarian hyperstimulation syndrome (OHSS)</measure>
    <time_frame>in 10 days after hCG injection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">348</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Antral follicle count</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start dose of recombinant Follicle-Stimulating Hormone (rFSH) based on AFC guide&#xD;
AFC &lt; 6 on both ovary: 375 IU FSH&#xD;
6&lt;AFC &lt;=15 on both ovary: 225 IU FSH&#xD;
AFC&gt; 15 on both ovary: 150 IU FSH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-Mullerian Hormone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start dose of FSH based on AMH guide&#xD;
AMH &lt; 5 pmol/L or &lt; 0.7ng/ml: 375 IU FSH&#xD;
AMH 5 to &lt; 15 pmol/L or 0.7 to 2.1ng/ml: 225 IU FSH&#xD;
AMH ≥ 15 pmol/L or &gt; 2.1ng/ml: 150 IU FSH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FSH</intervention_name>
    <arm_group_label>Anti-Mullerian Hormone</arm_group_label>
    <arm_group_label>Antral follicle count</arm_group_label>
    <other_name>GONAL-f</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Starting a treatment with GONAL-f® according to the decision of the investigator and&#xD;
             in accordance with the indication and dosing recommendation&#xD;
&#xD;
          -  Age &lt; 40 years at the time of GONAL-f® dosing&#xD;
&#xD;
          -  BMI &lt; 28 kg/m2&#xD;
&#xD;
          -  An early follicular phase (Day 2-4) serum levels of basal FSH ≤12 IU/L measured in the&#xD;
             site's own laboratory and taken within 2 months prior to down-regulation start&#xD;
&#xD;
          -  Receiving long Gonadotropin-Releasing Hormone (GnRH) agonist protocol (starting on day&#xD;
             21 of preceding cycle until day of hCG)&#xD;
&#xD;
          -  Agreement to participate in the study, and to disclose any medical events to the&#xD;
             investigator. The subject must be willing and able to comply with the protocol&#xD;
             requirements for the duration of the study.&#xD;
&#xD;
          -  Have given written informed consent with the understanding that the subject may&#xD;
             withdraw consent at any time without prejudice to future medical care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Simultaneous participation in an interventional clinical trial.&#xD;
&#xD;
          -  Concommitant use of either Luteinizing Hormone or human menopausal&#xD;
             gonadotropin/urinary FSH preparations in study cycle&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuong M Ho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vietnam National University HCMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Center for Genetics and Reproductive Health</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>January 17, 2013</study_first_submitted>
  <study_first_submitted_qc>January 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2013</study_first_posted>
  <last_update_submitted>January 31, 2013</last_update_submitted>
  <last_update_submitted_qc>January 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vietnam National University</investigator_affiliation>
    <investigator_full_name>Manh Tuong Ho</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>follicle stimulating hormone</keyword>
  <keyword>ovarian stimulation</keyword>
  <keyword>antimullerian hormone</keyword>
  <keyword>antral follicle count</keyword>
  <keyword>assisted reproductive technologies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

